Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1633–1656 of 2,086 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Rheumatoid Arthritis
Interventions: tocilizumab [RoActemra/Actemra], Placebo, Methotrexate; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 61
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 57 more

Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus
Interventions: Surovatamig; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Birmingham, Alabama • Fullerton, California • Plantation, Florida + 3 more

Conditions: Advanced Solid Tumors
Interventions: TAS-102 with a light tracer dose of [14C]FTD, TAS-102 with a light tracer dose of [14C] TPI, TAS-102 tablets; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alcohol Dependence
Interventions: Baclofen IR, Baclofen ER; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Urea Cycle Disorders
Interventions: HPN-100, NaPBA; Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 4 more

Conditions: Complex Regional Pain Syndrome I (CRPS I)
Interventions: Not listed
Lead sponsor: Ambros Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Schizophrenia
Interventions: Lurasidone; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 38
States / cities: Little Rock, Arkansas • Cerritos, California • Downey, California + 31 more

Conditions: Rheumatoid Arthritis
Interventions: Sarilumab, SAR153191 SC, Sarilumab, SAR153191 IV; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 12
States / cities: Centennial, Colorado • Clearwater, Florida • Hialeah, Florida + 9 more

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: Seladelpar, Placebos; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 14
States / cities: Glendale, Arizona • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: NSCLC, Breast Cancer
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Long Beach, California • Hattiesburg, Mississippi • New York, New York + 2 more

Conditions: Adjunctive Treatment of Major Depressive Disorder
Interventions: Pimavanserin; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 33
States / cities: Garden Grove, California • Glendale, California • Irvine, California + 26 more

Conditions: Paroxysmal Supraventricular Tachycardia
Interventions: Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System; Drug · Device
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Little Rock, Arkansas • Vista, California • West Hills, California + 14 more

Conditions: Asthma
Interventions: QGE031; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Evansville, Indiana • Owensboro, Kentucky • Waldorf, Maryland + 2 more

Conditions: Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions: ATYR1940; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 16 Years to 25 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Irvine, California • Stanford, California • Salt Lake City, Utah

Conditions: Glabellar Frown Lines
Interventions: Botulinum Toxin A, Placebo; Drug
Lead sponsor: Croma-Pharma GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Multiple Myeloma
Interventions: Teclistamab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Gilbert, Arizona • Denver, Colorado • Weston, Florida + 4 more

Conditions: Generalized Anxiety Disorder
Interventions: JNJ-99245354, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: Temecula, California • Miami, Florida • Springfield, Massachusetts + 1 more

Conditions: Covid 19
Interventions: Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C); Dietary Supplement
Lead sponsor: Endourage, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Novato, California

Conditions: Advanced Solid Tumor
Interventions: SGN1; Drug
Lead sponsor: Guangzhou Sinogen Pharmaceutical Co., Ltd; Other
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more

Conditions: Polycythemia Vera
Interventions: Rusfertide, Placebo; Drug
Lead sponsor: Protagonist Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 80
States / cities: Mobile, Alabama • Glendale, Arizona • Duarte, California + 66 more

Conditions: Tinnitus
Interventions: AM-101; Drug
Lead sponsor: Auris Medical, Inc.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Solid Tumors
Interventions: EC145; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Generalized Myasthenia Gravis
Interventions: Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 23
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more

Conditions: HIV-1-infection
Interventions: B/F/TAF, F/TAF, DTG, DTG Placebo, F/TAF Placebo, B/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 66
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 47 more

Search by objective public record fields.

A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors

ALK29-002: A Study of Baclofen Formulations in Healthy Adults

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

CRPS-RISE Outcomes Registry

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Phase 1b/2 Study of IV Sarilumab in Adult With RA

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia

Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

Study of SGN1 in Patients With Advanced Solid Tumor

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

AM-101 in the Treatment of Post-Acute Tinnitus 1

Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed